Free Newsletter
New U.S. research program to target mystery diseases
The National Institutes of Health has created a new research program that is devoting itself to studying patients with mystery diseases. The Undiagnosed Diseases Program will start to accept cases at their Bethesda center in July, taking patients whose disease confounds physicians. William Gahl, an expert on rare genetic diseases and the clinical director at the NIH's National Human Genome Research Institute, will be in charge.
"The history of biomedical research has taught us that careful study of baffling cases can provide new insights into the mechanisms of disease--both rare and common," says NIH director Elias Zerhouni (photo).
- read the report from AFP
Related Articles:
NIH expert sees new drive against rare disease
NIH budgets $71M to study rare diseases
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: